Lead Product(s) : N-Acetyl-D-Leucine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Sanford Burnham Prebys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-1211 is a potent and specific small-molecule inhibitor of TNAP. In vitro studies characterized the mode of inhibition and inhibitory effects of DS-1211 on three human ALP isozymes-TNAP, human intestinal ALP, human placental ALP.
Product Name : DS-1211
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : N-Acetyl-D-Leucine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Sanford Burnham Prebys
Deal Size : Inapplicable
Deal Type : Inapplicable